CRIS Current Research Information System

PALARETI, GUALTIERO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.308
EU - Europa 3.419
AS - Asia 1.758
AF - Africa 157
SA - Sud America 13
OC - Oceania 4
Totale 10.659
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.299
GB - Regno Unito 1.126
CN - Cina 688
DE - Germania 554
SG - Singapore 402
SE - Svezia 373
IT - Italia 365
VN - Vietnam 356
UA - Ucraina 303
IN - India 224
FR - Francia 164
IE - Irlanda 160
RU - Federazione Russa 142
ZA - Sudafrica 87
EE - Estonia 82
TG - Togo 33
JO - Giordania 31
CH - Svizzera 29
SC - Seychelles 25
FI - Finlandia 24
CZ - Repubblica Ceca 21
JP - Giappone 20
BE - Belgio 18
GR - Grecia 18
BG - Bulgaria 11
CA - Canada 9
CI - Costa d'Avorio 9
ID - Indonesia 9
CL - Cile 6
LB - Libano 6
HK - Hong Kong 5
NL - Olanda 5
AT - Austria 4
ES - Italia 4
RO - Romania 4
TR - Turchia 4
AU - Australia 3
BR - Brasile 3
PE - Perù 3
DK - Danimarca 2
HR - Croazia 2
IL - Israele 2
IR - Iran 2
KR - Corea 2
MA - Marocco 2
MY - Malesia 2
NO - Norvegia 2
PL - Polonia 2
SA - Arabia Saudita 2
SK - Slovacchia (Repubblica Slovacca) 2
UZ - Uzbekistan 2
AR - Argentina 1
LT - Lituania 1
MC - Monaco 1
MU - Mauritius 1
NZ - Nuova Zelanda 1
PH - Filippine 1
Totale 10.659
Salva come PNG Salva come JPEG
Città #
Southend 1.025
Fairfield 854
Ashburn 429
Woodbridge 383
Chandler 376
Seattle 368
Wilmington 364
Houston 358
Singapore 345
Cambridge 310
Princeton 277
Dong Ket 238
Ann Arbor 214
Jacksonville 200
Dublin 156
Nanjing 121
Westminster 111
Padova 101
Berlin 91
Santa Clara 67
Jinan 53
San Diego 53
Shenyang 51
Saint Petersburg 45
Turin 45
Hebei 41
Mülheim 39
Milan 37
Nanchang 36
Beijing 35
Changsha 35
Dearborn 35
Bologna 33
Lomé 33
Amman 31
Redmond 27
Des Moines 26
Bremen 23
Mahé 23
Bern 22
Helsinki 22
Boardman 21
Tianjin 20
Tokyo 19
Zhengzhou 19
Verona 18
Brussels 17
Hangzhou 16
Lanzhou 15
Norwalk 15
Bühl 14
Medford 14
Taizhou 14
Chicago 13
Guangzhou 13
Falls Church 12
Jiaxing 12
Shanghai 12
Haikou 11
Olalla 11
San Venanzo 11
Sofia 11
Taiyuan 11
Kunming 10
Abidjan 9
Jakarta 9
Los Angeles 9
Rome 8
London 7
Moscow 7
New York 7
Ningbo 7
Cesena 6
Foshan 6
Fuzhou 6
Redwood City 6
Chengdu 5
Frankfurt Am Main 5
Paris 5
Qingdao 5
Toronto 5
Washington 5
Catania 4
Frankfurt am Main 4
Harbin 4
Hefei 4
Kiev 4
Pune 4
Quanzhou 4
Shenzhen 4
Wuhan 4
Chongqing 3
Cleveland 3
Costa Mesa 3
Las Vegas 3
Lausanne 3
Listowel 3
Motta Sant'Anastasia 3
Orange 3
Piacenza 3
Totale 7.642
Salva come PNG Salva come JPEG
Nome #
A randomized double-blind study of low-molecular-weight heparin (parnaparin) for superficial vein thrombosis: STEFLUX (Superficial ThromboEmbolism and Fluxum). 174
Effects of unfractioned heparin and low-molecular-weight heparin on osteoprotegerin and RANKL plasma levels in haemodialysis patients. 169
Abnormal Protac-induced coagulation inhibition chromogenic assay results are associated with an increased risk of recurrent venous thromboembolism. 160
Comparison of results of percutaneous closure of patent foramen ovale for paradoxical embolism in patients with versus without thrombophilia. 157
Abnormally short activated partial thromboplastin time values are associated with increased risk of recurrence of venous thromboembolism after oral anticoagulation withdrawal. 148
A new rapid bedside assay for D-dimer measurement (Simplify D-dimer) in the diagnostic work-up for deep vein thrombosis. 147
A multicenter evaluation of a new quantitative highly sensitive D-dimer assay for exclusion of venous thromboembolism. 138
Hereditary thrombophilia and fetal loss: a prospective follow-up study. 136
Age and gender specific cut-off values to improve the performance of D: -dimer assays to predict the risk of venous thromboembolism recurrence. 134
Bleeding with anticoagulation therapy - who is at risk, and how best to identify such patients. 131
A multicentre randomised clinical endpoint study of PARMA 5 computer-assisted oral anticoagulant dosage. 129
Bridging therapy in oral anticoagulated patients: focusing on how to do it. 126
A commentary: to screen for calf DVT or not to screen? The highly variable practice among Italian centers highlights this important and still unresolved clinical option. Results from the Italian MASTER registry. 125
An international multicenter randomized study of computer-assisted oral anticoagulant dosage vs. medical staff dosage. 124
Long-term efficacy of transcatheter patent foramen ovale closure on migraine headache with aura and recurrent stroke. 123
Comparison between different D-Dimer cutoff values to assess the individual risk of recurrent venous thromboembolism: analysis of results obtained in the DULCIS study 117
The factor VIII D1241E polymorphism is associated with decreased factor VIII activity and not with activated protein C resistance levels. 116
High plasma levels of factor VIII and risk of recurrence of venous thromboembolism 115
D-dimer and factor VIII are independent risk factors for recurrence after anticoagulation withdrawal for a first idiopathic deep vein thrombosis. 113
D-Dimer testing for predictive recurrence risk in venous thromboembolism: looking for a useful threshold: reply to a rebuttal. 112
Comparison of five specific assays for determination of dabigatran plasma concentrations in patients enrolled in the START-Laboratory Register 112
HemosIL D-dimer HS assay in the diagnosis of deep vein thrombosis and pulmonary embolism. Results of a multicenter management study. 110
D-dimer for the diagnosis of upper extremity deep and superficial venous thrombosis 110
Familial thrombophilia and lifetime risk of venous thrombosis 109
Comorbidities, alone and in combination with D-dimer, as risk factors for recurrence after a first episode of unprovoked venous thromboembolism in the extended follow-up of the PROLONG study. 109
Fibrin D-dimer testing for venous and arterial thrombotic disease 107
Diagnosis of deep vein thrombosis. 106
D-dimer and residual vein obstruction as risk factors for recurrence during and after anticoagulation withdrawal in patients with a first episode of provoked deep-vein thrombosis. 106
Evolution of untreated calf deep-vein thrombosis in high risk symptomatic outpatients: the blind, prospective CALTHRO study. 105
Usefulness of repeated D-dimer testing after stopping anticoagulation for a first episode of unprovoked venous thromboembolism: the PROLONG II prospective study 104
Poor comparability of coagulation screening test with specific measurement in patients receiving direct oral anticoagulants: results from a multicenter/multiplatform study 103
Sex, age and normal post-anticoagulation D-dimer as risk factors for recurrence after idiopathic venous thromboembolism in the Prolong study extension. 102
Risk of a first venous thrombotic event in carriers of a familial thrombophilic defect. The European Prospective Cohort on Thrombophilia (EPCOT). 102
Transcatheter patent foramen ovale closure mitigates aura migraine headaches abolishing spontaneous right-to-left shunting 102
Analysis of agreement between duplex ultrasound scanning and arteriography in patients with lower limb artery disease 101
External validation of the DASH prediction rule: a retrospective cohort study 100
Oral contraceptive use in women with poor anticoagulant response to activated protein C but not carrying the factor V Leiden mutation increases the risk of venous thrombosis. 99
D-dimer, FVIII and thrombotic burden in the acute phase of deep vein thrombosis in relation to the risk of post-thrombotic syndrome 98
Low-intensity oral anticoagulant plus low-dose aspirin during the first six months versus standard-intensity oral anticoagulant therapy after mechanical heart valve replacement: a pilot study of low-intensity warfarin and aspirin in cardiac prostheses (LIWACAP). 97
Predictors of psychological state after genetic testing for inherited thrombophilia 96
D-dimer levels in combination with residual venous obstruction and the risk of recurrence after anticoagulation withdrawal for a first idiopathic deep vein thrombosis. 96
D-dimer, oral anticoagulation, and venous thromboembolism recurrence 95
The prothrombin time/international normalized ratio (PT/INR) Line: derivation of local INR with commercial thromboplastins and coagulometers--two independent studies. 95
Spontaneous large right-to-left shunt and migraine headache with aura are risk factors for recurrent stroke in patients with a patent foramen ovale. 94
D-dimer testing and recurrent venous thromboembolism after unprovoked pulmonary embolism: A post-hoc analysis of the Prolong extension study. 94
First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. 93
Warfarin anticoagulation in children made easier. 92
D-dimer testing and venous thromboembolism: four view points 91
Clinical characteristics and management of cancer-associated acute venous thromboembolism: findings from the MASTER Registry. 91
A new warfarin dosing algorithm including VKORC1 3730 G > A polymorphism: comparison with results obtained by other published algorithms 89
Stroke/thromboembolism and intracranial hemorrhage in a real-world atrial fibrillation population: The Complications of Atrial Fibrillation in the Bologna Area (CAFBO) study 89
High thrombin generation measured in the presence of thrombomodulin is associated with an increased risk of recurrent venous thromboembolism. 89
VASCULAR ENDOTHELIAL DYSFUNCTION IN PRIMARY OPEN ANGLE GLAUCOMA 89
Poor anticoagulation quality in the first 3 months after unprovoked venous thromboembolism is a risk factor for long-term recurrence. 88
Recurrence rate after a first venous thrombosis in patients with familial thrombophilia 88
Use of D-dimer testing to determine duration of anticoagulation, risk of cardiovascular events and occult cancer after a first episode of idiopathic venous thromboembolism: the extended follow-up of the PROLONG study. 88
Effects of unfractioned heparin and low-molecular-weight heparin on osteoprotegerin and RANKL plasma levels in hemodialysis patients 87
D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism: a management study 87
Accuracy of a portable prothrombin time monitor (Coagucheck) in patients on chronic oral anticoagulant therapy: A prospective multicenter study 87
Update on the predictive value of D-dimer in patients with idiopathic venous thromboembolism. 86
The negative predictive value of D-dimer on the risk of recurrent venous thromboembolism in patients with multiple previous events: A prospective cohort study (the PROLONG PLUS study). 86
Risk factors for venous thromboembolism in the elderly: results of the master registry. 86
Risks factors for highly unstable response to oral anticoagulation: a case-control study. 86
Risk of early recurrent fetal loss and levels of thrombin-activatable fibrinolysis inhibitor. 85
Psychological impact of testing for thrombophilic alterations. 85
Risk of deep vein thrombosis: interaction between oral contraceptives and high factor VIII levels. 85
Predicting the risk of recurrence of venous thromboembolism. 84
Is there a role for oral anticoagulant therapy in patients with peripheral arterial disease? 84
Residual emboli on lung perfusion scan or multidetector computed tomography after a first episode of acute pulmonary embolism. 82
Residual venous obstruction, alone and in combination with D-dimer, as a risk factor for recurrence after anticoagulation withdrawal following a first idiopathic deep vein thrombosis in the prolong study. 82
The predictive ability of bleeding risk stratification models in very old patients on vitamin K antagonist treatment for venous thromboembolism: results of the prospective collaborative EPICA study 81
Prevention of VTE in multiple myeloma patients. 80
Modulation of factor V levels in plasma by polymorphisms in the C2 domain. 80
null 80
Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). 80
The Wells rule and D-dimer for the diagnosis of isolated distal deep vein thrombosis 78
The influence of factor V Leiden and G20210A prothrombin mutation on the presence of residual vein obstruction after idiopathic deep-vein thrombosis of the lower limbs 78
Anticoagulation in Italian patients with venous thromboembolism and thrombophilic alterations: findings from START2 register study 77
Emerging drugs for venous thromboembolism. 76
Risk factors for recurrent events in subjects with superficial vein thrombosis in the randomized clinical trial SteFlux (Superficial Thromboembolism Fluxum) 75
Safety and Feasibility of a Diagnostic Algorithm Combining Clinical Probability, D-Dimer Testing, and Ultrasonography for Suspected Upper Extremity Deep Venous Thrombosis A Prospective Management Study 75
Low drug levels and thrombotic complications in high-risk atrial fibrillation patients treated with direct oral anticoagulants 75
D-dimer testing, with gender-specific cutoff levels, is of value to assess the individual risk of venous thromboembolic recurrence in non-elderly patients of both genders: a post hoc analysis of the DULCIS study 74
Endothelial activation in patients with superficial vein thrombosis (SVT) of the lower limbs 74
The predictive ability of bleeding risk stratification models in very old patients on vitamin K antagonist treatment for venous thromboembolism: results of the prospective collaborative EPICA study: reply 73
D-dimer testing to determine the duration of anticoagulation therapy. 73
The first ambulatory screening on thromboembolism: a multicentre, cross-sectional, observational study on risk factors for venous thromboembolism. 72
Assessment of patient capability to self-adjust oral anticoagulant dose: a multicenter study on home use of a portable prothrombin time monitor (COAGUCHECK) 72
Extended treatment for venous thromboembolism: how long is long enough? 70
Predictors of psychological state after genetic testing for inherited trombophilia 69
PROFILASSI DELLA MALATTIA TROBOEMBOLICA VENOSA IN CHIRURGIA BARIATRICA: STUDIO PROSPETTICO RANDOMIZZATO DI CONFRONTO TRA DUE DIFFERENTI DOSAGGI DI PARNAPARIN 68
D-dimer testing to determine the duration of anticoagulant therapy. 67
Old and new heparins. 66
FARMACODINAMICA DELL'EPARINA A BASSO PESO MOLECOLARE IN PAZIENTI SOTTOPOSTI A INTERVENTO DI CHIRURGIA BARIATRICA: STUDIO PROSPETTICO RANDOMIZZATO DI CONFRONTO TRA DUE DIFFERENTI DOSI DI PARNAPARIN (STUDIO BAFLUX) 66
Long-term risk for major bleeding during extended oral anticoagulant therapy for first unprovoked venous thromboembolism: A systematic review and meta-analysis 64
Prescribing anticoagulation medication for the elderly 60
"Early thrombus removal" in iliac-femoral deep vein thrombosis for prevention of post-thrombotic syndrome 60
La profilassi della malattia tromboembolica: valutazione dell’aderenza alle Linee di Indirizzo Aziendali per la Prevenzione delle Complicanze TromboEmboliche nell’Azienda Ospedaliero – Universitaria di Bologna 59
The direct oral anticoagulants may also be effective against the risk of post-thrombotic syndrome 59
Current criteria to determine the duration of anticoagulant therapy 57
Totale 9.563
Salva come PNG Salva come JPEG
Categoria #
all - tutte 28.875
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 28.875
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.629 0 0 0 190 339 365 382 415 460 210 116 152
2020/20211.632 344 133 28 79 32 97 48 103 163 117 84 404
2021/20221.870 199 59 169 125 224 109 49 164 70 86 273 343
2022/20231.923 244 278 112 252 119 148 53 89 285 68 175 100
2023/2024381 30 77 37 36 30 30 23 29 12 34 18 25
2024/2025835 66 484 150 135 0 0 0 0 0 0 0 0
Totale 10.922